Argos Therapeutics Inc (NASDAQ:ARGS) had its price target dropped by analysts at Stifel Nicolaus to $1.20 in a research report issued to clients and investors on Friday. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 41.18% from the stock’s current price.
Other equities research analysts also recently issued reports about the stock. FBR & Co reissued a “buy” rating and issued a $13.00 price objective on shares of Argos Therapeutics in a research report on Tuesday, January 17th. Zacks Investment Research raised shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Monday, January 16th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Argos Therapeutics in a research report on Friday, December 9th. Finally, JMP Securities downgraded shares of Argos Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 22nd. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $8.03.
Argos Therapeutics (NASDAQ:ARGS) opened at 0.85 on Friday. The firm’s market capitalization is $35.06 million. Argos Therapeutics has a 52-week low of $0.75 and a 52-week high of $13.97. The company’s 50-day moving average is $2.93 and its 200-day moving average is $4.34.
Your IP Address:
Several large investors have recently made changes to their positions in ARGS. State Street Corp increased its stake in shares of Argos Therapeutics by 11.7% in the fourth quarter. State Street Corp now owns 177,494 shares of the biopharmaceutical company’s stock worth $870,000 after buying an additional 18,625 shares in the last quarter. Sanders Morris Harris Inc. increased its position in Argos Therapeutics by 109.9% in the third quarter. Sanders Morris Harris Inc. now owns 241,512 shares of the biopharmaceutical company’s stock worth $1,201,000 after buying an additional 126,475 shares during the period. Finally, Wasatch Advisors Inc. increased its position in Argos Therapeutics by 35.2% in the third quarter. Wasatch Advisors Inc. now owns 3,228,741 shares of the biopharmaceutical company’s stock worth $16,047,000 after buying an additional 840,260 shares during the period. 15.25% of the stock is currently owned by institutional investors.
About Argos Therapeutics
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.